How AI and machine learning are transforming drug discovery
AI is revolutionizing drug discovery with its ability to analyze vast datasets. Particularly beneficial in the early drug discovery phase,…
sponsored
-
-
Bridging the gap: A comprehensive approach to social determinants of health
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in…
-
Podcast: The benefits of blockchain in healthcare
One of the key advantages of blockchain is that it removes the need for patients to provide the same information…
-
How Smart Digital Strategies are Leading the Way in Pharmaceutical Manufacturing
The evolution of pharmaceutical manufacturing is driven largely by the rising demands facing the industry. Inflation, strict regulations and a…
-
The long road to acceptance: The slow adoption of ion chromatography in the pharmaceutical industry
Introduction Ion chromatography (IC), a highly sensitive technique for separating and quantifying ionic species, was introduced in the 1970s and…
-
Customs simplified: the need to streamline pharma shipments
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially…
-
Podcast: AI and Supervised Machine Learning in Clinical Trials – Part 2
In episode two of The Zelta Podcast, we continue our conversation about AI and supervised machine learning in clinical trials…
-
Introducing AI into the pharma supply chain is a journey
The proliferation of Artificial Intelligence (AI) in our lives has set about a true revolution in how we collect, organize…
-
ePRO and eCOA: Digital solutions driving clinical trials engagement
Recruiting enough participants and keeping them engaged through lengthy clinical trials is increasingly challenging. In fact, more than 80% of…
-
How 3PL providers are gearing up for the wave of cell and gene therapies
The global cell and gene therapy (CGT) market is expanding at a rapid rate, and will be worth $76bn by…
